MEDP
Medpace Holdings, Inc.
$417.29
-6.71
(-1.58%)
Mkt Cap
11.92B
Volume
403,524
52W Range
284.48-628.916
Sector
Healthcare
Beta
1.19
EPS (TTM)
16.24
P/E Ratio
25.70
Revenue (TTM)
2.68B
Rev Growth (5Y)
+22.3%
EPS Growth (5Y)
+30.9%
AlphaVal · Fair Value
$604.80
Undervalued · Moderate
31.0% below fair value
AlphaQuality · Grade
A+
Platform & Compounding FCF
94.9 / 100 composite
Company Description
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.53B | 2.11B | 1.89B | 1.46B | 1.14B | 925.92M | 860.97M | 704.59M | 436.15M | 421.58M | 359.06M | 290.04M |
| Net Income | 451.12M | 404.39M | 282.81M | 245.37M | 181.85M | 145.38M | 100.44M | 73.19M | 39.12M | 13.43M | (8.67M) | (15.57M) |
| EPS | 15.64 | 13.06 | 9.20 | 7.57 | 5.06 | 4.07 | 2.79 | 2.05 | 1.00 | 0.38 | -0.28 | -0.53 |
| Free Cash Flow | 681.87M | 572.27M | 396.73M | 351.17M | 235.06M | 227.34M | 183.96M | 140.56M | 85.09M | 78.19M | N/A | N/A |
| FCF / Share | 23.64 | 18.49 | 12.91 | 10.84 | 6.55 | 6.38 | 5.13 | 3.95 | 2.18 | 2.19 | N/A | N/A |
| Operating CF | 713.22M | 608.82M | 433.37M | 388.05M | 263.33M | 258.68M | 201.87M | 156.58M | 97.39M | 91.73M | N/A | N/A |
| Total Assets | 1.98B | 2.10B | 1.66B | 1.35B | 1.66B | 1.39B | 1.14B | 967.93M | 950.72M | 979.11M | N/A | N/A |
| Total Debt | 250.50M | 149.52M | 142.12M | 188.87M | 130.97M | 115.14M | 45.21M | 79.72M | 221.61M | 163.64M | N/A | N/A |
| Cash & Equiv | 497.05M | 669.44M | 245.45M | 28.27M | 461.30M | 277.77M | 131.92M | 23.27M | 26.48M | 37.10M | N/A | N/A |
| Book Value | 459.07M | 825.54M | 558.95M | 386.39M | 952.93M | 805.78M | 726.28M | 589.70M | 503.53M | 610.71M | N/A | N/A |
| Return on Equity | 0.98 | 0.49 | 0.51 | 0.64 | 0.19 | 0.18 | 0.14 | 0.12 | 0.08 | 0.02 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 706.60M | 708.45M | 659.90M | 603.31M | 558.57M | 536.59M | 533.32M | 528.10M | 511.04M | 498.40M | 492.50M | 460.87M |
| Net Income | 123.87M | 135.13M | 111.14M | 90.26M | 114.59M | 117.02M | 96.43M | 88.35M | 102.59M | 78.30M | 70.55M | 61.07M |
| EPS | 4.35 | 4.78 | 3.95 | 3.16 | 3.77 | 3.78 | 3.11 | 2.85 | 3.32 | 2.55 | 2.30 | 2.00 |
| Free Cash Flow | 144.97M | 188.12M | 262.32M | 142.41M | 115.84M | 183.02M | 138.54M | 103.53M | 147.18M | 146.41M | 105.68M | 74.07M |
| FCF / Share | 5.10 | 6.65 | 9.04 | 4.83 | 3.81 | 5.91 | 4.46 | 3.34 | 4.77 | 4.77 | 3.45 | 2.43 |
| Operating CF | 151.79M | 192.65M | 246.21M | 148.53M | 125.84M | 190.67M | 149.07M | 116.40M | 152.68M | 156.40M | 114.39M | 82.52M |
| Total Assets | 2.13B | 1.98B | 1.75B | 1.57B | 1.90B | 2.10B | 2.08B | 1.92B | 1.80B | 1.66B | 1.49B | 1.41B |
| Total Debt | 146.09M | 250.50M | 143.97M | 149.83M | 126.66M | 126.23M | 128.28M | 131.80M | 136.16M | 142.12M | 143.04M | 194.39M |
| Cash & Equiv | 652.68M | 497.05M | 285.35M | 46.33M | 441.44M | 669.44M | 656.90M | 510.89M | 407.01M | 245.45M | 95.21M | 39.14M |
| Book Value | 598.31M | 459.07M | 293.64M | 172.35M | 593.61M | 825.54M | 881.44M | 763.60M | 671.54M | 558.95M | 470.91M | 391.06M |
| Return on Equity | 0.21 | 0.29 | 0.38 | 0.52 | 0.19 | 0.14 | 0.11 | 0.12 | 0.15 | 0.14 | 0.15 | 0.16 |
MEDP News
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
MEDP SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Defendants Allegedly Violated Securities Disclosure Laws: Levi & Korsinsky
PACS vs. MEDP: Which Stock Is the Better Value Option?
$MEDP Class Action Reminder: Medpace Class Action Deadline for Investors is June 8 – Contact BFA Law if You Lost Money
ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
INVESTOR ALERT: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law